~~<i id='D1C29B7435'><strike id='D1C29B7435'><tt id='D1C29B7435'><pre id='D1C29B7435'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

Wikipedia

author：Wikipedia 2025-09-27 23:32:22 - browse：335

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Former medical device CEO who sold dummy, plastic parts convicted of fraud

Wikipedia

leisure time

explore

hotspot

leisure time

MikeBellemeforSTATFiveyearsafterinvestor-ownedHCAHealthcaretookoveranesteemednonprofithospitalinNort

WSS

Medicare Advantage proposed rates disappoint insurers

The Readout: Gilead, Bernie Sanders, and other pharma news

The drug industry has found itself all alone in Washington

For Medicare Advantage, Democrats want stronger protections around AI

Biogen Alzheimer’s drug launch off to slow start

The problem with charging patients to message their doctors

knowledge

Wikipedia

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

The Readout: Gilead, Bernie Sanders, and other pharma news

Peter Hotez and the public health issue of online harassment

The drug industry has found itself all alone in Washington

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Jerome Adams on the need for new antivirals for Covid

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

The cancer drug shortage isn’t new — and neither are the solutions

Gilead might be held responsible for not developing a drug

leisure time

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Key House Republican on health care plans exit from Congress

Medicare threatens to cut off funding for HCA's Mission hospital

Gilead might be held responsible for not developing a drug

Sen. Paul opposes bill to ban Chinese biotechs

UnitedHealth quietly bought dozens of outpatient centers

leisure time

explore

hotspot

leisure time